Solitron Devices Q1 Revenue Doubles to $5.4M, Backlog Hits $27M, Hires Banker for Strategic Review
SODI sits 93% above its 52-week low of $14.23 on elevated volume (2.2× avg).
Summary
Solitron Devices reported Q1 FY2027 revenue of $5.44M (up 101% YoY), net income of $0.99M, and a backlog of $23.3M (plus $5M post-quarter order). The company also hired an investment banker to explore strategic alternatives.
Key Events · Earnings and Guidance · SODI
-
Revenue Doubles, Profit Swings Positive
Net sales surged 101% to $5.44 million in Q1 FY2027, with net income of $0.99 million ($0.46 per share) versus a loss of $0.34 million a year ago.
-
Backlog Strengthens to $27M
Backlog stood at $23.34 million at quarter-end, and a $5.04 million order received after the quarter lifts the effective backlog to $26.97 million as of July 2026.
-
Strategic Alternatives Review Initiated
The company retained an investment banker to explore a potential merger, sale, acquisition, tender offer, or special dividend, signaling a possible value-unlocking event.
-
AMRAAM Production Increase Proposed
The U.S. Air Force's unfunded priorities list requests doubling AMRAAM production to 2,400 annually by 2028 — a positive demand signal for Solitron's largest defense program.
Analysis · SODI · Manufacturing
A standout quarter saw revenue more than double year-over-year to $5.44 million, swinging the bottom line to a $0.99 million profit. The backlog remains robust at $23.34 million, and a $5.04 million order received after quarter-end pushes the effective backlog to nearly $27 million — providing strong visibility into future revenue. In a move that could unlock shareholder value, the company also disclosed it has retained an investment banker to explore strategic alternatives, including a potential sale or merger. These results and the strategic review mark a significant positive inflection for the micro-cap defense supplier.
At the time of this filing, SODI was trading at $27.50 on OTC in the Manufacturing sector, with a market capitalization of approximately $59.2M. The 52-week trading range was $14.23 to $30.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.